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AbstrAct
Na+/K+ pump or sodium- and potassium-activated adenosine 5’-triphosphatase (Na+, K+-AtPase), its 
enzymatic version, is a crucial protein responsible for the electrochemical gradient across the cell mem-
branes. It is an ion transporter, which in addition to exchange cations, is the ligand for cardenolides. this 
enzyme regulates the entry of K+ with the exit of Na+ from cells, being the responsible for Na+/K+ equilibrium 
maintenance through neuronal membranes. this transport system couples the hydrolysis of one molecule 
of AtP to exchange three sodium ions for two potassium ions, thus maintaining the normal gradient of 
these cations in animal cells. Oxidative metabolism is very active in brain, where large amounts of chemi-
cal energy as AtP molecules are consumed, mostly required for the maintenance of the ionic gradients that 
underlie resting and action potentials which are involved in nerve impulse propagation, neurotransmitter 
release and cation homeostasis. Protein phosphorylation is a key process in biological regulation. At nervous 
system level, protein phosphorylation is the major molecular mechanism through which the function of 
neural proteins is modulted in response to extracellular signals, including the response to neurotransmitter 
stimuli. It is the major mechanism of neural plasticity, including memory processing. the phosphorylation 
of Na+, K+-AtPase catalytic subunit inhibits enzyme activity whereas the inhibition of protein kinase c 
restores the enzyme activity. the dephosphorylation of neuronal Na+, K+-AtPase is mediated by calcineurin, 
a serine / threonine phosphatase. the latter enzyme is involved in a wide range of cellular responses to ca2+ 
mobilizing signals, in the regulation of neuronal excitability by controlling the activity of ion channels, in 
the release of neurotransmitters and hormones, as well as in synaptic plasticity and gene transcription. In 
the present article evidence showing Na+, K+-AtPase involvement in signaling pathways, enzyme changes 
in diverse neurological diseases as well as during aging, have been summarized. Issues refer mainly to Na+, 
K+-AtPase studies in ischemia, brain injury, depression and mood disorders, mania, stress, Alzheimer s´ dis-
ease, learning and memory, and neuronal hyperexcitability and epilepsy. (Int J Biomed Sci 2014; 10 (2): 85-102)
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INtrODUctION
Na+/K+, pump or sodium- and potassium-activated ad-
enosine 5’-triphosphatase (Na+, K+-ATPase), its enzymatic 
version, is a crucial protein responsible for the electro-
chemical gradient across the cell membranes. It is an ion 
transporter, which in addition to exchange cations, is the 
ligand for cardenolides. This enzyme discovered by Skou 
(1) is essential to establish and maintain high K+ and low 
Na+ concentration in the cytoplasm. It regulates the entry 
of K+ with the exit of Na+ from cells. Therefore, it is re-
sponsible for Na+ / K+ equilibrium maintenance through 
neuronal membranes. The impairment of such equilibria 
leads to nerve ending depolarization with Ca2+ entry to 
the cell. This is followed by neurotransmitter release and 
neuronal swelling, which is obviously detrimental to cell 
function. This transport system couples the hydrolysis of 
one molecule of ATP to exchange three sodium ions for 
two potassium ions, thus maintaining the normal gradient 
of these cations in animal cells (2, 3). 
Na+, K+-ATPase is a membrane-bound enzyme which 
is critical in neurons for the regulation of membrane po-
tential, cell volume and transmembrane fluxes of Ca2+ and 
excitatory neurotransmitters. It is also crucial in the nor-
mal cell cycle and differentiation of the nervous system. In 
specialized cells, the maintenance of Na+ and K+ gradients 
between the intracellular and extracellular compartments 
is a prerequisite for basic cellular homeostasis and for di-
verse functions (3). 
The activity of neuronal Na+, K+-ATPase concentrates 
in the surrounding nerve ending membranes. In these 
membranes specific receptors for classical neurotransmit-
ter and neuropeptides are also inserted (4-6). All these 
macromolecules are most likely localized contiguously 
and therefore may well interact at central nervous system 
(CNS). The possibility of their regulation by released ac-
tive substances at synapses seems tenable.
It is known that oxidative metabolism is very active 
in brain, where large amounts of chemical energy as ATP 
molecules are consumed, mostly required for the mainte-
nance of the ionic gradients that underlie resting and action 
potentials which are involved in nerve impulse propaga-
tion, neurotransmitter release and cation homeostasis (3). 
Na+, K+-ATPase is the pharmacological receptor for car-
diotonic steroids such as ouabain and digoxin, which behave 
as enzyme inhibitors (7). Cardiotonic steroids are synthesized 
in the brain (8) and are present in the hypothalamus of Milan 
hypertensive rats (7). A 3D-structural model of the Na+, K+-
ATPase digitalis binding site has been constructed (9).
To maintain neuronal cytoplasmic Ca2+ concentration 
one-ten thousand times lower that in the extracellular mil-
lieu, two mechanisms are involved: a calcium pump and 
a Na+ / Ca2+ exchanger. The latter depends on functional 
Na+, K+-ATPase, in a process inhibited by omitting Na+ and 
including ouabain. Therefore, failure of the Na+, K+-pump 
produces depletion of intracellular K+, accumulation of 
intracellular free Ca2+ by activation of voltage-gated Ca2+ 
channels and reversion of the Na+ / Ca2+ exchanger (10).
NA+, K+-AtPAse regUlAtION by PhOsPhOr-
ylAtION/DePhOsPhOrylAtION
It is known that protein phosphorylation is a key process 
in biological regulation. It involves a protein kinase, a pro-
tein phosphatase and a substrate protein. The kinases cata-
lyze the transfer of the terminal g phosphate of ATP to the 
hydroxyl moiety in the correponding amino acid residue, in 
a reaction which requires Mg2+. In turn, the protein phos-
phatases catalyze the cleavage of this phosphoester bond 
through hydrolysis. Phosphorylation of diverse protein types 
is involved in regulating or in carrying out nervous system 
processes. At nervous system level, protein phosphoryla-
tion is the major molecular mechanism through which the 
function of neural proteins is regulated in response to extra-
cellular signals, including the response to neurotransmitter 
stimuli. Indeed, it is the major mechanism of neural plastic-
ity, including memory processing. Regarding the subject of 
the present article, it should be recalled that Na+, K+-ATPase 
is a phosphorylation substrate (11). 
The phosphorylation of Na+, K+-ATPase catalytic sub-
unit inhibits enzyme activity (12). Accordingly, inhibition 
of protein kinase C (PKC) restores the enzyme activity (13, 
14). The dephosphorylation of neuronal Na+, K+-ATPase is 
mediated by calcineurin, a serine / threonine phosphatase. 
The latter enzyme is involved in a wide range of cellu-
lar responses to Ca2+ mobilizing signals, in the regulation 
of neuronal excitability by controlling the activity of ion 
channels, in the release of neurotransmitters and hor-
mones, as well as in synaptic plasticity and gene transcrip-
tion (15, 16). Besides, changes in dopamine- and cAMP-
regulated phosphoprotein of 32 kDa (DARPP-32) activity 
may well lead to altered protein phosphatase 1 activity and 
hence to modified Na+, K+-ATPase dephosphorylation (17).
brAIN NA+, K+-AtPAse strUctUre
Na+, K+-ATPase is an olygomeric enzyme consisting 
of α and β subunits, both required for enzyme function 
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(Fig. 1). Alpha subunit is the catalytic one which exists in 
different isoforms: α1, α2, α3, or α4, the latter identified 
only in testis (18). The binding sites for ATP and the in-
hibitor ouabain as well as ion occlusion occur in α subunit 
(19). In the brain there are present isoforms α1, α2 and α3 
which have cell-type and development-specific expression 
patterns. Subunits α1, α2, and α3 bind inhibitor ouabain 
with low, intermediate and high affinity, respectively. In 
neurons are present the last two isoforms whereas in glial 
cells are localized α1 and α2 isoforms (20-23).
The α2 isoform is widely expressed in neurons in late 
gestation but it is primarily expressed in astrocytes in 
adult brain. Most interesting, mice lacking the α2 isoform 
do not survive after birth (24).
Na+, K+-ATPase activity is regulated by some neu-
rotransmitters (25-27). Such regulation is dependent on 
ontogeny (28). It is worthwhile to recall that all three 
α-subunit isoforms are present in neurons from the neo-
striatum and isoform specificity for neurotransmitter-de-
pendent regulation of Na+, K+-ATPase activity has been 
suggested (29). 
The b subunit regulates both the activity and the con-
formational stability of α subunit (30, 31) and seems to be 
involved in the modulation of enzyme affinity for K+ and 
Na+ (32, 33). It is important for ATP hydrolysis, ion trans-
port, and binding of inhibitors such as ouabain. The b sub-
unit must interact with α subunit in order to accomplish 
ion transport (2). 
In association with the αb dimmer there is a third 
subunit (γ) which belongs to the FXYD family proteins. 
This subunit modulates transport function of the enzyme 
(34), seems not essential for functional Na+, K+-ATPase 
but most likely plays a regulatory role in a tissue-specific 
manner (2, 35). The mammalian FXYD proteins from 
FXYD1 to FXYD7 exhibit tissue-specific distribution 
(36). They are considered to be regulators of ion chan-
nels or channels themselves. The function of these pro-
teins is to modulate Na+, K+-ATPase catalytic properties 
by molecular interactions with specific enzyme domains 
(37, 38) (Fig. 1).
It is known that plasma membrane expression of the 
Na+, K+-ATPase requires the assembly of its α- and b- sub-
units. There is an interaction between the Na+, K+-ATPase 
α-subunit and the coat protein, b-COP, a component of the 
COP-1 complex. In the absence of the b- subunit the Na+, 
K+-ATPase α-subunit interacts with b-COP, is retained in 
the endoplasmic reticulum and targeted for degradation. 
In the presence of the b- subunit the α-subunit traffics di-
rectly to the plasma membrane (39). 
NA+, K+-AtPAse AND sIgNAlINg PAthWAys 
Evidences support the notion that Na+, K+-ATPase acts 
as a signal transducer (40 as illustrated in Fig. 2. Na+, K+-
ATPase forms a complex with Src, a non-receptor tyrosine 
kinase, which functions as a signal receptor for cardioton-
ic steroids. Src inhibition blocks many of the ouabain-acti-
vated signaling pathways. Binding of ouabain to Na+, K+-
ATPase modifies the enzyme interaction with neighboring 
membrane proteins inducing the formation of multiple 
signaling modules which lead to Src kinase activation, 
transactivation of the epidermal growth factor receptor 
(EGFR) and increase formation of reactive oxygen species 
(41). The interaction of such signals results in the activ-
ity of several cascades, including the activation of phos-
pholipase C (42). Multiple protein kinase cascades result 
activated, including mitogen-activated protein kinases and 
protein kinase C (PKC) isozymes in a cell-specific man-
ner. Mitochondrial production of reactive oxygen species 
(ROS) is activated and intracellular calcium concentration 
regulated. Cross-talk among the activated pathways may 
lead to changes in the expression of a number of genes (43).
Signaling Na+, K+-ATPase seems concentrated in an 
separate pool on the plasma membrane and potential inter-
action between Na+, K+-ATPase and caveolins was studied, 
due to enzyme concentration in caveloae/rafts (41, 44).
Figure 1. Schematic representation of Na+, K+-ATPase struc-
ture. The enzyme is a heterodimeric membrane spanning pro-
tein which is composed by α and β subunits, and, in some cases 
the γ (FXYD) subunit. The α subunit contains ten transmem-
brane domains whereas the β and γ subunits contain a single 
transmembrane domain. From reference 131, with permission.
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In rat cardiac and renal cells, a cascade of events occur 
following ouabain interaction with a minor fraction of Na+, 
K+-ATPase. After sodium pump inhibition by ouabain, in-
tracellular Na+ concentration increases which is followed 
by a gradual enhancement or oscillations in intracellular 
Ca2+ concentration. Such increase in intracellular Ca2+ 
concentration may be part of or a result of the cascade; 
alternatively, it may be a totally independent phenomenon 
(45). This process most likely involves stimulation of a 
clathrin-dependent endocytosis pathway leading to Na+, 
K+-ATPase translocation to intracellular compartments, 
thus suggesting a role of endocytosis in ouabain-induced 
signal transduction (46).
A 20-amino acid peptide (NaKtide) has been identi-
fied from the nucleotide binding domain of α1 Na+, K+-
ATPase that binds and inhibits Src in vitro. Replacement 
of residues in NaKtide reduces or abolishes the inhibitory 
effect of the peptide on Src. However, a mutant α1 Na+, K+-
ATPase that retains normal ion pumping but is defective in 
Src regulation has been described (47). 
Although binding of endogenous cardiotonic steroids 
at sub-nanomolar ranges may not cause significant inhi-
bition of Na+, K+-ATPase activity, they are able to pro-
voke multiple protein kinase signaling events (Fig. 2). 
Such events include extracellular signal regulated kinase 
(ERK) cascades, PLC/PKC pathways, PI3K/Akt signal-
ing and mitochondrial production of ROS (48). Na+, K+-
ATPase interaction with Src forms a receptor complex 
for cardiotonic steroids to relay its extracel lular binding 
site to intracellular signaling events. At least two pairs of 
domain–domain interactions are involved. The Na+, K+-
ATPase second cytosolic domain binds Src SH2 domain, 
while the N domain directly associates with Src kinase 
domain and inhib its Src activation. Cardiotonic steroids 
binding to Na+, K+-ATPase induces conformational chang-
es which provide the driving force to release the Src kinase 
domain from the N domain. In turn, it triggers the activa-
tion of Src, which transactivates receptor tyrosines such as 
EGF receptor, resulting in the assembly and activation of 
protein kinase cascades such as Ras/Raf/ERK and PLC. 
As a consequence, PLC activation generates IP3 and dia-
cylglycerol, which lead to increases in cytosolic Ca2+ and 
PKC activation. Therefore, the Na+, K+-ATPase can form 
a Src-coupled receptor. In this complex (Fig. 2), the Na+, 
K+-ATPase provides the ligand-binding site, and the asso-
ciated Src acts as a signal transducer, capable of convert-
ing and amplifying the binding signal through lipid and 
protein kinase cascades (48). 
In addition to binding Src, the Na+, K+-ATPase inter-
acts with many other proteins. Some of them are moesin 
(49) and cofilin (50) which are related to actin. Other pro-
teins are arrestin 2 and spinophilin (51) and PI3K p85 sub-
unit (52), all involved in the modulation of Na+, K+-ATPase 
endo cytosis.
The enzyme N-terminus also interacts with IP3R, Na+/
Ca2+ exchanger and caveolin-1 (Fig. 2). These interac-
tions bring the transporters and their regulatory proteins 
together favouring the formation of signaling complexes, 
allowing spatial and temporal regulation of signal trans-
duction and coordination with trans membrane transport. 
Such interactions are also impor tant for establishing stable 
membrane structures such as lipid rafts (53). Moreover, 
Figure 2. Na+, K+-ATPase-mediated signal transduction. Na+, 
K+-ATPase forms a signaling complex composed of multiple 
structural proteins (ankyrin, caveolin), receptors (IP3R, EGFR), 
and protein and lipid kinases (Src-kinase, PI3K). Binding of 
ouabain to an extracellular site on Na+, K+-ATPase leads to con-
formational changes in the enzyme that modify its interactions 
with the intracellular proteins. Ouabain binding induces activa-
tion of both the PI3K/Akt pathway and the Src/EGFR/Ras/Raf/
MEK/ERK kinase cascade. In turn, these events promote PLC-
catalyzed production of IP3 and DAG, which activate IP3R in the 
ER membrane and PKC. IP3R, depicted as the 6-TM structure 
in the ER membrane, is the Ca2+ channel that will release Ca2+ 
(yellow hexagon) from the ER to the cytoplasm in response to 
an increase in IP3. Ankyrin is involved in organizing the Na+, 
K+-ATPase–IP3R complex. Akt, protein kinase B; DAG, diacyl-
glycerol; EGFR, epi dermal growth factor receptor; ER, endo-
plasmic reticulum; ERK, extracellular-signal regulated protein 
kinase; IP3, inositol 1,4,5-trisphosphate; IP3R, IP3 receptor; 
NCX, Na,Ca antiporter; PI3K, phosphatidylinositol 3-kinase; 
PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phospha-
tidylinositol (3,4,5)-trisphosphate; PKC, protein kinase C; PLC, 
phospholipase C; ROS, reactive oxygen species. The large red 
arrows depict caveolin in the flask-shaped caveolae. From refer-
ence 3, with permission.
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there are coordinated oligomolecular complexes of Na+, 
K+-ATPase with gluta mate transporters (54) and aquapo-
rin 4 (55) among other macromolecules.
In diverse neurological pathologies it is of interest to 
consider the relationship between Na+, K+-ATPase with its 
scaffolding partners in the regulation of caveolae, cell mo-
tility and tight junctions (53, 56, 57). Other relationshps 
include enzyme binding with PI3K and with annexin II to 
regulate cell motility (56).
Activation of Na+, K+-ATPase signaling by cardiotonic 
steroids leads to enzyme endocytosis which most likely 
involves Src or PI3K (Fig. 2). Functionally, cardiotonic ste-
roids-induced endocytosis of Na+, K+-ATPase serves as a 
basis to terminate the signal, to relay the signal or to target 
it to specific intracellu lar compartments (58). For detailed 
refer ences and reviews of the physiological and pathologi-
cal func tions of cardiotonic steroids (7, 48). 
It is known that Na+, K+-ATPase signal transduction 
triggers dendritic growth, and transcriptional programs 
dependent on cyclic AMP response element binding pro-
tein (CREB) and CRE-mediated gene expression, primar-
ily regulated via Ca2+/calmodulin-dependent kinases (59). 
As mentioned above, the major source of energy de-
mand in neurons is the Na+, K+-ATPase pump that restores 
ionic gradients across the plasma membrane subsequent 
to depolarizing neuronal activity. The energy comes 
mainly from mitochondrial oxidative metabolism, being 
cytochrome oxidase a key enzyme. All cytochrome oxi-
dase subunits are regulated by the neuron-specific factor 
Sp4 (59). At the same time, Sp4 regulates Atp1a1, Atp1a3, 
and Atp1b1 subunit genes of Na+, K+-ATPase in neurons. 
The expression of these genes is activity-dependent be-
cause it is up-regulated by depolarizing KCl stimulation 
and down-regulated by impulse blocker tetrodotoxin (59). 
Taken jointly, these observations indicate that Sp4 plays 
an important role in the transcriptional coupling of energy 
generation and energy consumption in neurons (59). 
In the present article available experimental evi-
dence was reviewed, which shows the alteration of 
Na+, K+-ATPase at CNS during aging and in patho-
logical conditions.
brAIN NA+, K+-AtPAse ActIVIty DUrINg De-
VelOPMeNt AND AgINg
Brain Na+, K+-ATPase increases roughly 10 times (10-
fold) during development, and the increase is due to accu-
mulation of the enzyme itself (60, 61). Thyroid hormone, 
known to be a regulator of brain Na+, K+-ATPase during 
development (62, differentially regulates enzyme isoforms 
(61, 63). 
Na+, K+-ATPase activity in synaptosomal fractions de-
creases with aging in normoxic rats. The decrease in this 
enzyme activity by aging is more marked during adapta-
tion to chronic intermittent severe hypoxia (64).
There are cell- and isoform- specificity alterations of 
Na+, K+-ATPase α isoform mRNAs in aging rat hippocam-
pus (65) and cerebellum (66). Besides, the expression of 
enzyme α1 mRNA increases whereas that of α3 mRNA 
decreases in aging rat cerebral cortex (67).
In cerebellar Purkinje neurons of rats there is a pro-
gressive increase in resting membrane potential as well 
as in the depolarizing action of ouabain. Such increase 
correlates with that of ouabain binding sites in whole cer-
ebellum. The increases in ouabain binding and the elec-
trophysiological responses to ouabain seem a consequence 
of increases in the sodium pump. Assays with antibodies 
against Na+, K+-ATPase subunits show an increase in the 
relative amount of α3 subunit with no change in the levels 
of α1 or α2 subunits (68).
Studies carried out in crude microsomal preparations 
indicate that there is increased tendency in rat brain Na+, 
K+-ATPase activity from newborn to 18 days of age, sug-
gesting that the sodium pump is mature soon after birth. 
No significant diferences are recorded between newborn 
and adult rats. Na+, K+-ATPase activity in aged rat brains 
is significantly lower than that at other stages of brain de-
velopment. The suggestion that aged-induced decrease in 
brain Na+, K+-ATPase may be related to the depression of 
neuronal excitability and the impairement of cognitive 
functions has been advanced (69). 
Evidence indicates that both water content and Na+, 
K+-ATPase activity in rat brain are significantly reduced 
during aging (70). Synaptosomal resting membrane poten-
tial and Na+, K+-ATPase activity decrease significantly in 
senescence. The decrease in phosphatidylcholine content 
during aging may be, at least in part, responsible for dimin-
ished enzyme activity due to alteration of lipid microenvi-
ronment. The latter, which regulates the enzyme activity, 
starts to change early during aging, which is followed by 
a decrease in Na+, K+-ATPase content. Taken jointly, these 
findings suggest that both changes cooperatively decrease 
Na+, K+-ATPase activity in senescence (71-73). 
Other authors described that Na+, K+-ATPase activity 
(74) and ouabain binding sites (75) in human CNS as well 
as Na+, K+-ATPase activity, 3H-ouabain binding sites, or 
their affinity for ouabain in rat CNS (76) do not change 
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with age. Curiously enough, synaptosome Na+, K+-ATPase 
activity in female rat brain decreases with aging whereas 
it remains elevated in male rat brain (77). 
When brain crude synaptosomes are exposed in vitro to 
an oxidative stress by a combination of Fe2+ and ascorbate 
for up to two hours there is lipid peroxidation, extensive 
protein carbonyl formation and a marked decrease of Na+, 
K+-ATPase activity. All these changes are prevented by the 
presence of butylated hydroxytoluene, a chain-breaking 
anti-oxidant. In brain synaptosomal membrane prepara-
tions lower enzyme activity with elevated levels of lipid 
peroxidation products and protein carbonyls are detected 
in the aged rats in comparison with the young ones. These 
findings lead to the conclusion that age-related decline of 
rat brain Na+, K+-ATPase activity is most likely the conse-
quence of enhanced oxidative damage in aging brain (78). 
In the superior frontal cortex occurs a decrease in Na+, 
K+-ATPase α3-mRNA content per individual neuron dur-
ing normal aging. This change is observed prior to the for-
mation of Alzheimer diffuse plaques (79).
Aging induces specific changes in individual ATPases 
according to their subsynaptic localization. ATPase cat-
alytic activities tend to decrease by aging. The cerebral 
concentration and content of somatic plasma membrane 
proteins increases by aging. This observation suggests 
that many defective noncatalytic proteins may be formed 
during aging, as disclosed by immunoblotting techniques 
(80). Na+, K+-ATPase activity in hippocampus is lower in 
39 days-old rats versus 16 days-old rats (81).
Cognitive deficits occur in the aged brain (82). L-depre-
nyl protects against such deficit by improving long-term 
learning and memory in the aged brain. Evidences indi-
cate that chronic deprenyl administration enhances basal 
electrical firing rate and the activities of Na+, K+-ATPase 
and PKC in CA1 and CA3 hippocampal areas, sites at 
which initial learning and memory processes occur (83). 
Na+, K+-ATPase of synaptic plasma membranes in adult 
and aged animals is stimulated by ischemia. This hyper-
activity is more marked in adult than in aged animals. The 
abnomarlities persist after 72 and 96 hours during the re-
circulation times, which indicate the delayed postischemic 
suffering of the brain. The changes in ATPase catalytic 
activity in synaptic membranes, modified by ischemia in 
presynaptic terminals, may exert an important functional 
role during the recovery time in cerebral tissue in vivo, 
mainly in response to noxious stimuli, particularly during 
the recirculation period from acute or chronic brain injury 
(84).
The activity of synaptosomal membrane Na+, K+-
ATPase is modified by catecholamines, an effect depen-
dent of the presence of brain soluble factors (25, 26). The 
effect of catecholamines and soluble factors varies with 
rat aging. In older rats (one year old) strong inhibitory ef-
fect is observed whereas in young rats (two weeks old) no 
changes in enzyme activity are recorded (28).
NA+, K+-AtPAse ActIVIty AND blOOD Pres-
sUre regUlAtION
Results obtained with different experimental models 
suggest a relationship between blood pressure and brain 
Na+, K+-ATPase activity regulation. This notion is based 
on the effect of Na+, K+-ATPase inhibitors, termed oua-
bain-like substances. There are evidences which favour 
the notion that brain ouabain-like activity may be involved 
in the pressor responses to high sodium in Dahl salt-sen-
sitive rats (85).
After aortic constriction which increases blood pres-
sure, brain Na+, K+-ATPase expression and activity change. 
In whole brain, at one week after constriction all α enzyme 
isoforms are depressed. At four weeks, the mRNA levels 
of all Na+, K+-ATPase α isoforms increase in whole brain 
in parallel with the enhancement of α2 and α3 transcripts 
in hypothalamus. The initial decrease in this enzyme ex-
pression and activity may contribute to hypertension while 
the increase in the α2 / α3 brain expression and activity 
at four weeks is most likely a compensatory response to 
established hypertension (86).
On the other hand, examination of Na+, K+-ATPase 
preparations from the Milan hypertensive strain and the 
spontaneous hypertensive rats indicate that sensitivity to 
Na+ and inhibition curves for ouabain and mercury fail 
to differ from those recorded in enzyme preparations ob-
tained from normotensive rats. These findings rule out that 
drastic structural alterations of the transport system occur 
in brain of hypertensive animals (87). 
brAIN NA+, K+-AtPAse ActIVIty IN PAthO-
lOgIcAl cONDItIONs
The activity of Na+, K+-ATPase is reduced or is insuf-
ficient for the maintenance of an adequate ionic balance 
during and after episodes of epilepsy, hypoglycemia or 
ischemia, as well as after the administration of excito-
toxins like glutamate agonists. Na+, K+-ATPase inhibition 
at presynaptic level impairs the sodium gradient which 
drives the uptake of a variety of neurotransmitters. As a 
consequence, it results in the blockade of reuptake and 
Na+, K+-aTPase iN agiNg aNd disease
www.ijbs.org    Int  J  Biomed  Sci    vol. 10  no. 2    June  2014 91
stimulation release of glutamate and other neurotransmit-
ters which modulate glutamate neurotoxicity (88).
Two types of brain edema may be discriminated, which 
are characterized by intra- or extracellular fluid accumula-
tion. Intracellular edema occurs after cerebral ischemia, 
trauma, metabolic disorders and intoxications. Mecha-
nisms involved include: a) a failure of active Na+ export via 
Na+, K+-ATPase due to energy shortage, b) an enhanced 
Na+ permeability, or c) the activation of Na+ driven mem-
brane pumps. Extracellular edema occurs in brain tumors, 
infections, trauma and hypertensive crisis. It is caused by 
damage of the blood-brain barrier and is accompanied by 
protein-rich fluid (89).
Administration of Na+, K+-ATPase inhibitors ouabain, 
digoxin and digitoxin antagonize the antinociceptive ef-
fect of morphine in mice. This effect is not attributable to 
an interaction at opioid receptors. The suggestion that the 
activation of Na+, K+-ATPase plays a role in the supraspi-
nal, but not spinal, antinociceptive effect of morphine has 
been formulated (90).
IscheMIA
Acute cerebral ischemia induced by middle cerebral ar-
tery occlusion leads to changes in Na+, K+-ATPase activity, 
water content as well as Na+ concentration. The cellular 
edema seems associated with impaired membrane pump 
function (91). Focal cerebral ischemia is associated with 
a decrease in Na+, K+-ATPase activity and in alteration in 
affinity of enzyme sites for ouabain. Only two sites for 
ouabain are detected though all three α isoforms are pres-
ent. No changes in protein and mRNA expression of α or β 
isoforms are recorded. The suggestion that ischemia leads 
to intrinsic modifications in Na+, K+-ATPase, which result 
in alteration of membrane integrity and / or association of 
the α isoforms has been advanced (92, 93).
Aplication of single transient forebrain ischemia in 
adult rats causes inhibition of Na+, K+-ATPase activity 
in hippocampal and cerebral cortex membrane fractions. 
Ischemic preconditioning prevents the inhibitory effect 
of ischemia / reperfusion on Na+, K+-ATPase activity. It 
has been hypothesized that the maintenance of Na+, K+-
ATPase activity afforded by preconditioning is related to 
neuronal protection (94).
In an experimental model of ischemic preconditioning 
carried out in hippocampal slice cultures two regulators 
has been identified: protein kinase M zeta and the Na+, K+-
ATPase. Whereas at short time (two hous) following pre-
conditioning there is neither alteration of the regulators or 
neuroprotection, at longer period (24 hours) there is enhance-
ment of protein kinase M zeta and the Na+, K+-ATPase. Most 
interestingly, inhibition of α1 and α2 / α3 Na+, K+-ATPase 
isoforms blocks neuroprotection following ischemic precon-
ditioning. The roles of the mentioned regulators in persistent 
neuroprotective mechamism of ischemic preconditioning 
have been advanced. These findings lead to the conclusion 
that increased Na+, K+-ATPase activity protects slice culture 
neurons from hypoxia-hypoglycemia (95).
It is known that ouabain inhibits Na+, K+-ATPase activ-
ity within the 10-7-10-3 M concentration range but stimulates 
this enzyme activity at lower ranges (96). The stimulatory 
effect of cardiotonic steroids is recorded in hippocampal 
slice cultures in vitro as well as in hippocampus in vivo. 
Ouabain protects slice culture neurons from experimental 
ischemia at concentrations that enhanced Na+, K+-ATPase. 
These observations suggested that the protective effect of 
ouabain is due to increased Na+, K+-ATPase activity (97). 
A hypoxic precondition induces neuroprotection 
against transient global ischemia in adult rats. This result 
is due to enhanced recovery of Na+, K+-ATPase activity by 
preservation of protein levels of enzyme α1 subunit and 
reduced DNA fragmentation after ischemia (98).
brAIN INJUry
Cryogenic lesion to brain produces different changes in 
water content and Na+, K+-ATPase activity according to rat 
age. The increase in water content was larger in adult rats 
whereas impairement of Na+, K+-ATPase activity is more 
pronounced in aged animals (70). 
In experimental traumatic brain injury there is a de-
crease in brain Na+, K+-ATPase activity concomitant with 
an increase in the levels of lipid / protein oxidation. At the 
same time, an alteration in membrane fluidity and neuro-
nal excitability is observed (99).
Pearson s´ correlation analysis discloses strong corre-
lation of myeloperoxidase increase with Na+, K+-ATPase 
inhibition in sedentary rats. Previous running exercise 
(4 weeks) protects against fluid percussion brain injury 
(FPI)-induced and motor function impairement and fluo-
rescein extravasation. Physical training is effective against 
myeloperoxidase activity increase and Na+, K+-ATPase ac-
tivity decrease after FPI. This protection correlates with 
myeloperoxidase activity decrease and indicates that the 
alteration of cerebral inflamatory status profile observed 
by previous physical training diminishes initial damage 
and limits long-term secondary degeneration after trau-
matic brain injury (100). 
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DePressION AND MOOD DIsOrDers
Diverse evidences suggest the involvement of Na+, K+-
ATPase dysfunction in the pathophysiology of unipolar and 
bipolar disorder (101). A model for mood cycle regulation 
has been proposed involving steroid hormones by means 
of Na+, K+-ATPase regulation; this hypothesis contends 
that steroid hormones decreases Na+, K+-ATPase activity 
in hypothalamus, directly or through their conversion into 
digitalis-like compounds, which in turn, stimulate beta-en-
dorphin secretion, normally leading to elevated mood (102). 
Evidences indicate that depressive disorders result 
from a combination of inherited susceptibility genes and 
environmental stress (103). A reduction in Na+, K+-ATPase 
expression and function is associated with depressive dis-
orders in humans (104-107) as well as in animal models of 
depression (108, 109). In a model of depression employing 
female rat reduction in hippocampal synaptic membrane 
Na+, K+-ATPase activity has been observed. Treatment 
with fluoxetine enhances the enzyme activity and reverses 
the effect of stress, suggesting that altered Na+, K+-ATPase 
activity may well be involved in the pathophysiology of 
depression in patients (108). 
There is a reduction of Sp4 protein levels in the cer-
ebellum and prefrontal cortex of bipolar disorder subjects, 
supporting a possible role of this factor in the pathogen-
esis of the disease. Besides, Sp4 stability is regulated by 
neuronal activity and lithium stabilizes Sp4 protein. These 
observations suggested that normalization of Sp4 levels 
could contribute to treatment of affective disorders (109).
Na+, K+-ATPase α3 heterozygous mice develop en-
hanced depression-like endophenotypes in a chronic vari-
able stress paradigm in comparison to wild-type litter-
mates (Atp1a3(+/+)). In Atp1a3(+/+) mice chronic variable 
stress fails to decrease Na+, K+-ATPase activity. Therefore, 
a mutation that diminishes neuronal Na+, K+-ATPase activ-
ity exacerbates depression induced by stress. An interest-
ing correlation between Na+, K+-ATPase activity and mood 
in unipolar and bipolar disorders has been advanced (110). 
On the other hand, inhibition of calcineurin, which 
leads to Na+, K+-ATPase activity decrease, induces depres-
sive-like behavior via mTOR signaling pathway (111).
MANIA
Findings suggest a relationship between Na+, K+-
ATPase α3 subunit and mania. Intracerebroventricular 
administration of ouabain induces behavioral changes in 
a rat model of mania (112-115). 
Regarding to this point, it is of interest to consider the 
involvement of agrin, a proteoglycan which behaves as an 
antagonist for Na+, K+-ATPase α3 subunit and exerts regu-
latory properties of brain function. Through its inhibition 
of Na+, K+-ATPase α3 subunit, agrin is important in Ca2+ 
homeostasis and neuronal activity (116).
Myshkin mice which carry an inactivating mutation in 
the Na+, K+-ATPase α3 subunit display a behavioral profile 
very similar to bipolar patients in the maniac state. These 
mice present increased Ca2+ signaling in cultured cortical 
neurons and phosphoactivation of ERK and Akt in hippo-
campus. Most interesting, specific ERK inhibitor SL327 
and transgenic expression of a functional Na+, K+-ATPase 
α3 subunit rescue the mania-like phenotype of Myshkin 
mice (117). The expression of agrin has been related to 
Myshkin mice behaviour and agrin has been proposed as 
a potential therapeutic target for the treatment of mania 
and other neurological pathologies related to reduced Na+, 
K+-ATPase activity and neuronal hyperexcitability (118).
stress
Na+, K+-ATPase activity in rat CNS is influenced by 
neonatal handling. Enzyme activity decreases in hip-
pocampus but increases in the amigdala of neonatally-
handled rats. Chronic variable stress diminishes Na+, K+-
ATPase activity in hippocamppus, amigdala and parietal 
cortex. Therefore, early handling increases the ability to 
cope with chronic variable stress in adulthood. At that 
stage, animals show less susceptibility to neurochemical 
features related to depression, supporting the relevance of 
the precocious environment to vulnerability to psychiatric 
disorders in adulthood (119). 
Exposure of rats to repeated restraint stress reduces the 
levels of Na+, K+-ATPase in brain structures and changes 
both short- and long-term memory, learning and explor-
atory response (120).
NeUrONAl hyPereXcItAbIlIty AND ePI-
lePsy
The common pathogenetic factor for a congenital sta-
tus convulsivus has been attributed to a defect of astrocyte 
Na+, K+-ATPase (121).
At the time of convulsions induced by pentylenetet-
razol a considerable swelling of astroglial cells occurs as 
disclosed at the electron microscope level. Concomitantly, 
Na+, K+-ATPase activity in rat cerebral cortex homogenates 
is higher than that in the controls. At variance, the activi-
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ties of Mg2+-ATPase, K+- and Mg2+-p-nitrophenylphospha-
tases remain unaltered by the treatment (122).
There is an increase of Na+, K+-ATPase activity in the 
primary focus of cat cerebral cortex produced by acute 
freeze lesions. Both K+ and phenytoin dephosphorylating 
influences are decreased in primary and secondary foci of 
acutely lesioned cats. In chronic cats, the dephosphorylating 
step of Na+, K+-ATPase catalytic subunit recovers a normal 
affinity to K+ whereas its sensitivity to phenytoin remains 
diminished. It has been advanced that such differences in K+ 
and phenytoin influences on brain Na+, K+-ATPase between 
control versus epileptic cortex might be responsible for the 
ictal transformation and seizure spread (123).
Potential regulatory mechanisms for extracellular K+ 
concentration during spontaneous recurrent epileptiform 
activity was studied. During hyperactivity induced in the 
dentate gyrus of hippocampal slices from rats by perfu-
sion with potassium, the effect of several drugs was tested. 
Results obtained in this experimental model with tetrodo-
toxin, furosemide, barium and cesium salts, and ouabain, 
lead to the conclusion that potassium redistribution by glia 
only plays a minor role whereas the major regulator of 
extracellular K+ concentration seems to be ion uptake via 
Na+, K+-ATPase, most likely the neuronal one (124).
Partial inhibition of Na+, K+-ATPase with the low affin-
ity cardiac glycoside dihydroouabain produces neuronal 
hyperexcitability in CA1 hippocampal slices. Such effect 
is attributable to reduced GABAergic potentials and en-
hanced coupling between excitatory postsynaptic poten-
tials and spike firing (125).
A1A2 Na+, K+-ATPase mutations occur in familial 
hemiplegic migraine type 2 (FHM2) (126). Three putative 
A1A2 mutations have been identified. Among them, those 
termed D718N and P979L, may predispose to seizures and 
mental retardation (127).
The activity of Na+, K+-ATPase in hippocampus in-
creases after multiple status epilepticus induced by pilo-
carpine in developing rats. The increases are notably high-
er when the assays are carried out at 30 days versus 7 days 
following the injections (81). 
Familial hemiplegic migraine is a form of migraine with 
aura associated with several neurological signs, including 
epileptic seizures (128). The sporadic form of hemiplegic 
migraine presents with the same symptoms (129). In a case 
of a young hemiplegic migraine patient epileptic seizures 
occurred in the childhood which was controlled with drug 
therapy. This sporadic case carries a nonsense muration 
p.Tyr1009X in the ATP1A2 gene, leading to a truncated α2 
subunit of the Na+, K+-ATPase thus lacking the last 11 amino 
acids. This mutation confirms the role of this gene in forms 
of hemiplegic migraine associated with epilepsy (130).
It is known that the two autosomal dominantly inher-
ited neurological diseases: familial hemiplegic migraine 
type 2 and familial rapid-onset of dystonia-parkinsonism 
are caused by mutations of specific α subunits of Na+, K+-
ATPase. Patients with classical symptoms of these diseases 
suffer other manifestations, such as epileptiform activity. 
Mouse models targeting a specific α isoform produce com-
parable phenotypes consistent with classical symptoms 
observed in familial hemiplegic migraine type 2 and fa-
milial rapid-onset of dystonia-parkinsonism patients (131). 
Dopamine oxidation products exert diverse damag-
ing effects on brain subcellular components. It is known 
that dopamine causes in vitro neuronal Na+, K+-ATPase 
inhibition (25, 132). The inactivation of neuronal Na+, K+-
ATPase by dopamine may lead to various toxic sequelae 
with potential implications for dopaminergic cell death in 
Parkinson s´ disease (132).
It is known that ouabain-induces hyperactivity in rats 
(112-115) and ouabain binding to Na+, K+-ATPase affects 
in vitro signaling molecules, most likely ERK1/2 and Akt, 
which promote protein translation (43, 133).
Ouabain injection to rats leads to hyperactivity and 
increased phosphorylation levels of mTOR, p70S6K, S6, 
elF4B and 4E-BP. Findings suggest that ouabain adminis-
tration induces activation of the protein translation initia-
tion pathway regulated by ERK1/2 and Akt, and prolonged 
hyperactivity in rats (134). 
It is known that traumatic brain injury is a major cause 
of acquired epilepsy. Exercise training is effective against 
several neurochemical alterations including the inhibition of 
Na+, K+-ATPase activity after fluid percussion injury (135).
AlZheIMer DIseAse
Alzheimer disease is a neurodegenerative disorder 
characterized clinically by progressive memory and cog-
nitive dysfunction associated to neuronal loss. Autopsy 
from patients clinically and histopathologically diagnosed 
as having Alzheimer disease exhibit several criteria which 
include the accumulation of amyloid-beta (Aβ) peptide 
plaques and neurofibrillary tangles (NFTs) in the brain. 
The levels of Aβ and tau/phospho-tau in the cerebrospinal 
fluid are associated with this pathology (136, 137). 
There is a marked decrease in brain ouabain binding in 
patients with Alzheimer disease in comparison with age 
matched controls, particularly in the cerebral cortex (75). 
In relation with impaired neuronal function, the activity 
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of Na+, K+-ATPase is significantly lower in the brains of 
patients with Alzheimer s´ disease than in the brains of 
normal controls (138).
The exposure of cultured rat hippocampal neurons to Aβ 
peptide leads to selective reduction of Na+, K+-ATPase activ-
ity which precedes the loss of calcium homeostasis and cell 
degeneration. The treatment fails to impair the activity of 
Mg2+-dependent ATPase or that of the Na+/Ca2+ exchanger. 
Inhibition of Na+, K+-ATPase activity with ouabain is suf-
ficient to induce elevation of Ca2+ and neuronal injury. Neu-
ronal degeneration produced by ouabain seems to be due 
to an apoptotic form as indicated by nuclear condensation 
and DNA fragmentation. Besides, the exposure of synap-
tosomes isolated from postmortem human hippocampus to 
Aβ specifically reduces Na+, K+-ATPase and Ca2+-ATPase 
activities, without altering the activity of Mg2+-dependent 
ATPase or that of the Na+/Ca2+ exchanger. These find-
ings lead to the suggestion that impairement of ion-motive 
ATPase activities may be important for the pathogenesis of 
neuronal injury in Alzheimer disease (139). 
Amyloid impairs glucose transport in hippocampal 
and cortical neurons, an effect which involves membrane 
lipid peroxidation (140). This peroxidation may well ex-
plain the reduction of Na+, K+-ATPase activity. Oxidative 
stress, mitochondrial dysfunction, and impairment of Na+, 
K+-ATPase activity in hippocampal neurons induced by 
amyloid are attenuated by basic fibroblast growth factor 
(bFGF). Na+, K+-ATPase activity is significantly reduced 
following exposure to Aβ (25-35) toxicity in control hip-
pocampal cultures but not in cultures pre-treated with 
bFGF (141). Impairement of Na+, K+-ATPase activity by 
amyloid beta-peptides in rat hippocampal cultures (141) is 
not readily reversible and occurs only after amyloid in-
cubation with intact hippocampal slices but not with dis-
rupted membranes (142).
In superior frontal cortex from Alzheimer disease 
subjects there occurs an increase in α1-mRNA Na+, 
K+-ATPase, most likely related to enhanced reactive 
gliosis. At the same time, there is a decrease in Na+, 
K+-ATPase α3-mRNA. The suggestion that the declines 
in α3-mRNA per neuron which occurs in normal ag-
ing may predispone to or potentiate Alzheimer disease 
pathogenesis has been advanved (79). Na+, K+-ATPase 
activity and enzyme α3 subunit are lower in Alzheimer s´ 
disease brains versus control brains. In contrast, the 
amount of protein disulfide isomerase, which is one of 
the house keeping membrane proteins, fails to differ be-
tween groups (143).
Evidences support a key role for protein phosphoryla-
tion in both normal and pathological actions of Aβ and 
the formation of NFTs. Protein kinases are involved in the 
actions of tau or Aβ. However, protein phosphatases such 
as serine/threonine protein phosphatases that reverse the 
actions of protein kinases are important likewise in the 
pathology of Alzheimer s´ disease (144). 
Calcineurin may play an especial role in Alzheimer s´ 
disease because it modulates Na+, K+-ATPase activity. Calci-
neurin protein levels are inversely correlated with dementia 
severity and Braak tangle stage in the brain of patients with 
Alzheimer disease (145). Soluble Aβ oligomers activate cal-
cium-dependent phosphatase calcineurin (PP2B) which in 
turn activates the transcriptional nuclear factor of activated 
T cells (NFAT). Aβ deposits are ameliorated by calcineurin 
inhibition, supporting the notion the calcineurin-NFAT are 
aberrantly activated by Aβ and that calcineurin-NFAT ac-
tivation is responsible for disruption of neuronal structure 
close to the plaques. The conclusion that neurodegeneration 
in Alzheimer disease, at least partially, occurs by activation 
of calcineurin followed by NFAT-mediated downstream 
cascades has been advanced (146).
Diverse evidences support the notion that Aβ oligomers 
are the drivers of neurodegeneration which occurs in Al-
zheimer disease (147). Some of the pathways involve the 
activation of glutamatergic metabotropic mGluR5 recep-
tor (148) and that of caspase-3 which leads to Akt1 cleav-
age (149). Other interactions with Na+, K+-ATPase activity 
include ERK2 downregulation as well as the N-methyl-D-
aspartate (NMDA) ionotropic glutamate receptor activation 
(150, 151), closely related to Na+, K+-ATPase activity (Fig. 3). 
In fact, results recorded in several experimental models 
suggest a close relationship between the activity of Na+, K+-
ATPase and NMDA receptor in intact cells (152-154). Aβ 
oligomers modify the activity of calcineurin (146), known 
to enhance Na+, K+-ATPase activity by its dephosphory-
lation (15, 16). Besides, Ca2+ influx through the NMDA 
receptor activates calcineurin and protein phosphatase 1, 
thus modifying Na+, K+-ATPase activity (155). 
NA+, K+-AtPAse INVOlVeMeNt IN leArNINg 
AND MeMOry
Inhibition of Na+, K+-ATPase activity produces edema 
and cell death at CNS level and also impairs learning and 
memory. Several sex steroid hormones protect against neu-
ronal cell damage and disfunction of learning and memory. 
Accordingly, 17beta-estradiol and testosterone ameliorate 
amnesia induced by ouabain, a non-genomic effect which is 
independent of radical scavenging action (156). 
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It is known that cognitive deficits occur in the aged 
brain. L-deprenyl protects against such deficit by improv-
ing long-term learning and memory in the aged brain. 
Evidences indicate that chronic deprenyl administration 
enhances basal electrical firing rate and the activities of 
Na+, K+-ATPase and PKC in CA1 and CA3 hippocampal 
areas, sites at which initial learning and memory processes 
occur (83). 
DIAbetes 
It is known that insulin is one of the many hormones 
which regulate the activity of Na+, K+-ATPase. Alteration 
of this enzyme activity has been associated to diverse dia-
betic complications (157). Insulin enhances the activity of 
membrane-bound ATPase isolated from rat brain (158), an 
effect which is dependent on both: the experimental assay 
condition and the integrity of some cell membranes (159). 
Relatively high hormone concentrations are required to 
obtain maximal insulin effect. Such effect most likely in-
volves the high affinity enzyme isoform (160).
Streptozotocin administration to laboratory animals 
exerts a specific toxic effect to the pancreatic beta cells, 
which undergo their destruction by necrosis inducing a 
diabetic state (161). This state is associated with a reduc-
tion in brain Na+, K+-ATPase activity (162-164). Changes 
recorded in α3 isoform expression and Na+, K+-ATPase ac-
tivity are dependent on the time elapsed after drug admin-
istration (162). Findings suggested that the drug may alter 
first per se isoform expression. In time, the lower enzyme 
activity may be a consequence of the hyperglycemic dia-
betic state (165).
cANcer
Evidences showing the involvement of Na+, K+-ATPase 
in regulating carcinoma cell motility have been reported 
(56). Na+/K+ pump is directly involved in the migration 
of cancer cells in general and of glioma cells in particu-
lar. The Na+, K+-ATPase α1 subunit is highly expressed 
in glioma cells versus normal brain tissue and has been 
propossed as a new target for malignant glioma treatment 
(166). Glioblastoma patients resistant to chemotherapy and 
whose tumors over-express Na+, K+-ATPase α1 subunit 
could benefit from a treatment using ligands with higher 
binding affnity for the enzyme α subunit (167).
It has been reported that the frecuency of strong FXYD3 
expression is higher in the primary tumors in comparison 
to normal brain tissue. Increases in FXYD3 expression are 
higher in females than in males and in multiple site glio-
mas than in single sites. This result suggests that FXYD3 
expression may be involved in glioma development, speti-
ally in multiple gliomas and female patients (168).
cONclUDINg reMArKs AND FUtUre DI-
rectIONs
Diverse lines of evidence lead to the notion that Na+, 
K+-ATPase (sodium pump) exerts vital roles in normal 
brain function. Na+, K+-ATPase is concentrated in the syn-
aptic membranes where it participates in diverse important 
reactions involved in neurotransmission. For this reason, a 
fine tuning of this enzyme activity is essential. Inhibition 
of Na+, K+-ATPase by ouabain impairs several biochemical 
Figure 3. Molecular mechanisms proposed for Aβ synapto-
toxicity. The diagram summarizes some pathways which have 
been invoked in several experimental paradigms for synapto-
toxicity. Aβ directly or indirectly modifies glutamate receptor-
dependent cascades, which in turn lead to LTP impairement 
and LTD facilitation. Activation of calcineurin and NFATc4 
induces dystrophic changes in neurites, and calcineurin-depen-
dent dephoshorylation of CaMKII impairs the induction of 
AMPAR-based LTP in hippocampus. Other changes induced 
by Aβ include upregulation of α7-nAcCh receptor, tau phos-
phorylation and caspase-3 activation which also lead to LTP 
impairement. mGluR5, metabotropic glutamate receptor 5; 
ERK2, extracellular signal-regulated kinase 2; MAPK, mito-
gen-activated protein kinase; JNK, c-Jun N-terminal kinase; 
Cdk5, cyclin-dependent kinase 5; GSK-3β, glycogen synthase 
kinase-3β; Akt1, serine-threonine protein kinase 1; NMDAR, 
N-methyl-D-aspartate receptor; AMPAR, α-amino-3-hydroxyl-
5-methyl-4-isoxazolepropionate receptor; CaMKII, calmodu-
lin kinase II; PKA, protein kinase A; PP1, protein phosphatase 
1; NFATc4, nuclear factor of activated T-cells; α7-nAcChR, 
α7-nicotinic acetylcholine receptor; BDNF, brain-derived neu-
rotrophic factor: CREB, cyclic AMP response element binding 
protein. For a complete description, see reference 147. From ref-
erence 147, with permission.
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and physicochemical activities. To illustrate, incubation 
of isolated synaptosomes with ouabain inhibits oxidative 
metabolism, the synthesis of high energy compounds, pro-
teins and lipids, as well as the uptake of neurotransmit-
ters and their precursors. Likewise, ouabain blocks both 
potassium uptake and sodium release, which are required 
to restore ionic equilibria after the passage of nervous im-
pulse (169). These facts indicate that it is important that 
Na+, K+-ATPase could function adequately. Otherwise, its 
malfuctioning could obviously lead to diverse alterations 
of neuronal behaviour.
It should be considered that Na+, K+-ATPase changes 
recorded in a given pathological condition may involve a 
direct effect on enzyme expression or activity. Alterna-
tively, they may be due to indirect effects following the 
alteration of neurotransmitter receptors which are closely 
located in the synaptic membranes. 
There are domain-specific interactions which make the 
enzyme Na+, K+-ATPase an important scaffold in form-
ing signaling microdomains. By direct or indirect interac-
tions, it is able to modify numerous enzymes and intra-
cellular factors which are involved in signaling pathways, 
including Src and many other proteins. Some of them 
modulate Na+, K+-ATPase endocytosis, are related to ac-
tin, or include IP3R, Na+ / Ca2+ exchanger or caveolin-1. 
Other interactions favour the formation of stable mem-
brane structures such as lipid rafts and oligomolecular 
complexes with gluta mate receptors and transporters and 
aquaporin 4, among other macromolecules.
Regarding neuronal excitability with Na+, K+-ATPase 
activity, there is the notion that its malfunctioning is 
currently associated with neuronal hyperexcitability 
(81). An ultraslow, minute-long afterhyperpolarization 
in network neurons following locomotor episodes has 
been described. It is mediated by an activity- and sodium 
spike-dependent enhancement of electrogenic Na+/K+ 
pump function. The ultraslow hyperpolarization seems 
related to short-term memory of neural network function 
via activity-dependent potentiation of Na+/K+ pump func-
tion (170).
On the other hand, the activation of the limbic-hypo-
thalamic-pituitary-adrenal axis and the release of gluco-
corticoids are fundamental for the adaptive response and 
immediate survival of an organism in response to acute 
stimuli. However, high levels of glucocorticoids in brain 
may lead to neuronal injury and decreased Na+, K+-ATPase 
activity, affecting neurotransmitter signaling, neural ac-
tivity and animal behavior (120).
Studies with existing cardiac glycosides or other oua-
bain-like substances termed endobains (27) could provide 
an adecuate path toward clinical tests for ischemic stroke. 
Such studies can play a role in the identification of new 
candidate drugs as well as drug targets for the treatment of 
diseases for which adequate therapeutic pathways are not 
available nowadays. 
The availability of a wide spectrum of Na+, K+-ATPase 
enzyme isoforms mutations represents a valuable tool to 
disclose the mechanisms involving this enzyme in diverse 
neurological pathologies. Moreover, the use of mouse 
models offers broad potentials for future research concen-
ing migraine and dystonia-related diseases (131).
It is known that ifenprodil (a NMDA receptor antago-
nist) restores both Na+, K+-ATPase expression and GDNF-
evoked Ca2+ signalling Na+, K+-ATPase expression in in-
flammation-pretreated astrocytes (171). This observation 
offers another potential relationship to take into account 
in neurological diseases involving Na+, K+-ATPase expres-
sion and NMDA receptor deficiency.
As mentioned above, evidences show that in Alzheim-
er disease patients Na+, K+-ATPase activity is lower than in 
control patients. On the other hand, Sp4 levels are dramati-
cally increased and associated with neurofibrillary tangles 
and pathological tau presence in neurons of the CA1 hip-
pocampus region and entorhinal cortex of Alzheimer dis-
ease patients (171). Taken into account that Sp4 regulates 
the expression of Na+, K+-ATPase subunit genes in neu-
rons (59), the sodium pump may be a target in translational 
medicine. 
Regarding potential brain function recovery after trau-
ma, it is of interest to recall that physical exercise produc-
es favorable effects in neuroreabilitation after traumatic 
brain injury (100).
It is tempting to advance that the employ of pharma-
ceuticals to block Na+, K+-ATPase inhibition by endog-
enous substances or to enhance Na+, K+-ATPase activity 
may be of help to treat depressive disorders or to avoid 
depressive disorders in susceptible individuals. 
cONFlIct OF INterest 
The authors declare that no conflicting interests exist.
AcKNOWleDgMeNts
G. R. de L. A. is chief investigator from the Consejo 
Nacional de Investigaciones Científicas y Técnicas (CONI-
CET). The authors are indebted to CONICET and Univer-
sidad de Buenos Aires, Argentina, for financial support.
Na+, K+-aTPase iN agiNg aNd disease
www.ijbs.org    Int  J  Biomed  Sci    vol. 10  no. 2    June  2014 97
AbbreVIAtIONs
reFereNces
 
1. Skou J. The influence of some cations on an adenosine triphosphatase 
from peripheral nerves. Biochim. Biophys. Acta. 1957; 23: 394-401.
2. Scheiner-Bobis G. The sodium pump. Its molecular properties and 
mechanics of ion transport. Eur. J. Biochem. 2002; 269: 2424-2433.
3. Albers RW, Siegel GJ. Membrane transport. In: Brady ST, Siegel 
GJ, Albers RW, Price D (Eds.). Basic Neurochemistry: Principles of 
Molecular, Cellular and Medical Neurobiology, 8th edn. Massachu-
setts, USA: Elsevier Academic Press. 2012; p41-62.
4. De Robertis E. The synaptosome. Two decades of cell fractionation of 
the brain. Intern. Brain Res. Org. Monogr. Ser. 1983; 10: 1-10.
5. Rodríguez de Lores Arnaiz G, Alberici M, De Rober tis E. Ultrastruc-
tural and enzymic studies of cholinergic and non-ch oli nergic synap-
tic membranes isolated from brain cortex. J. Neu rochem. 1967; 14: 
215-225. 
6. Mains RE, Eiper BA. Peptides. In: Brady ST, Siegel GJ, Albers RW, 
Price D (Eds.). Basic Neurochemistry: Principles of Molecular, Cellu-
lar and Medical Neurobiology, 8th edn. Massachusetts, USA: Elsevier 
Academic Press. 2012; p390-419.
7. Lingrel JB. The Physiological Significance of the Cardiotonic Steroid/
Ouabain-Binding site of the Na,K-ATPase. Ann. Rev. Physiol. 2010; 
72: 395-412.
8. Bagrov AY, Shapiro JI, Fedorova OV. Endogenous cardiotonic ster-
oids: physiology, pharmacology, and novel therapeutic targets. Phar-
macol. Rev. 2009; 61: 9-38.
9. Keenan SM, DeLisle RK, Welsh WJ, Paula S, Ball WJ Jr. Elucidation 
Aβ peptide amyloid-beta peptide MeK mitogen-activated protein kinase kinase 
(MARK kinase)
Akt, protein 
kinase b (PKb)
serine/threonine-specific protein kinase NaKtide Na+, K+-ATPase 20-amino acid peptide
Atp1a1, Atp1a3, 
and Atp1b1
Na+, K+-ATPase mutants Na+, K+-AtPase sodium- and potassium-activated adenosine 
5’-triphosphatase
bFgF basic fibroblast growth factor NcX Na+, Ca2+ antiporter
cNs central nervous system NFAt nuclear factor of activated T cells
creb cyclic AMP response element binding protein NFts neurofibrillary tangles
DAg diacylglycerol NMDA recep-
tor
N-methyl-D-aspartate ionotropic glutamate 
receptor
DArPP-32 cAMP-regulated phosphoprotein of 32 kDa PP2b calcium-dependent phosphatase calcineurin
4e-bP translational regulator protein PI3K phosphatidylinositol 3-kinase
elF4b initiation factor PIP2 phosphatidylinositol 4,5-bisphosphate
egF epidermal growth factor PIP3 phosphatidylinositol (3,4,5)-trisphosphate
egFr epidermal growth factor receptor PKb protein kinase B
er endoplasmic reticulum PKc protein kinase C
erK extracellular-signal regulated protein kinase Plc phospholipase C
FhM2 familial hemiplegic migraine type 2 ras proteins small GTPases that regulate cell growth, 
proliferation and differentiation
FPI fluid percussion brain injury raf kinases family of three serine/threonine-specific 
protein kinases
FXyD Na+, K+-ATPase γ subunit rOs reactive oxygen species
Ic50 half maximal inhibitory concentration sl327 specific ERK inhibitor
IP3 inositol 1,4,5-trisphosphate sp4 sprouty 4 factor
IP3r IP3 receptor src-kinase non-receptor tyrosine kinase
ltD long term depression mtOr mammalian target of Rapamycin, serine/
threonine kinase
ltP long term potentiation p70s6K serine/threonine protein kinase that phos-
phorylates the ribosomal S6 subunit
Mg2+-AtPase magnessium-activated adenosine 5’-triphos-
phatase
s6 a component of the 40S ribosomal subunit
Na+, K+-aTPase iN agiNg aNd disease
June  2014    Vol. 10  No. 2    Int  J  Biomed  Sci    www.ijbs.org 98
of the Na+, K+-ATPase digitalis binding site. J. Mol. Graph. Model. 
2005; 23: 465-475.
10. DiPolo R, Beaugé L. Regulation of Na-Ca exchange. An overview. 
Ann. N. Y. Acad. Sci. 1991; 639: 100-111. 
11. Plattner F, Bibb JA. Serine and Threonine Phosphorylation. In: Brady 
ST, Siegel GJ, Albers RW, Price D (Eds.). Basic Neurochemistry: Prin-
ciples of Molecular, Cellular and Medical Neurobiology, 8th edn. Mas-
sachusetts, USA: Elsevier Academic Press. 2012; p467-492.
12. Bertorello AM, Aperia A, Walaas SI, Nairn AC, et al. Phosphorylation 
of the catalytic subunit of Na+, K+-ATPase inhibits the activity of the 
enzyme. Proc. Natl. Acad. Sci. USA. 1991; 88: 11359-11362.
13. Hermenegildo C, Felipo V, Miñana MD, Grisolía S. Inhibition of pro-
tein kinase C restores Na+, K+-ATPase activity in sciatic nerve of dia-
betic mice. J. Neurochem. 1992; 58: 1246-1249.
14. Hermenegildo C, Felipo V, Miñana MD, Romero FJ, et al. Sustained 
recovery of Na(+)-K(+)-ATPase activity in the sciatic nerve of diabetic 
mice by administration of H7 or calphostin C, inhibitors of PKC. Dia-
betes. 1993; 42: 257-262.
15. Yakel JL. Calcineurin regulation of synaptic function: from ion chan-
nels to transmitter release and gene transcription. Trends Pharmacol. 
Sci. 1997; 18: 124-134.
16. Rusnak F, Mertz P. Calcineurin: form and function. Physiol. Rev. 2000; 
80: 1483-1521.
17. Li D, Aperia A, Celsi G, da Cruz e Silva EF, et al. Protein phospha-
tase-1 in the kidney: evidence for a role in the regulation of medullary 
Na(+)-K(+)-ATPase. Am. J. Physiol. 1995; 269: F673-F680. 
18. Shamraj OI, Lingrel JB. A putative fourth Na+, K(+)-ATPase alpha-
subunit gene is expressed in testis. Proc. Natl. Acad. Sci. USA. 1994; 
91: 12952-12956.
19. Antolovic R, Bruller H J, Bunk S, Linder D, Schoner W. Epitope map-
ping by amino-acid-sequence-specific antibodies reveals that both 
ends of the alpha subunit of Na+/K(+)-ATPase are located on the cyto-
plasmic side of the membrane. Eur. J. Biochem. 1991; 199: 195-202. 
20. Sweadner KJ. Isozymes of Na+, K+-ATPase. Biochim. Biophys. Acta. 
1989; 988: 185-220.
21. Berrebi-Bertrand I, Maixent JM, Christe G, Leleièvre LG. Two active 
Na+/K+-ATPases of high affinity for ouabain in adult rat brain mem-
branes. Biochim. Biophys. Acta. 1990; 1021: 148-156.
22. McGrail KM, Phillips JM, Sweadner KJ. Immunofluorescent localiza-
tion of three Na,K-ATPase isozymes in the rat central nervous system: 
both neurons and glia express more than one Na, K-ATPase. J. Neuro-
sci. 1991; 11: 381-391.
23. Cholet N, Pellerin L, Magistretti PJ, Hamel E. Similar perisynaptic 
glial localization for the Na+, K+-ATPase alpha 2 subunit and the gluta-
mate transporters GLAST and GLT-1 in the rat somatosensory cortex. 
Cerebr. Cortex. 2002; 12: 515-525.
24. Moseley AE, Lieske SP, Wetzel RK, James, PF, He S, et al. The Na,K-
ATPase alpha 2 isoform is expressed in neurons, and its absence dis-
rupts neuronal activity in newborn mice. J. Biol. Chem. 2003; 278: 
5317-5324.
25. Rodríguez de Lores Arnaiz G. Neuronal Na / K-ATPase and its regula-
tion by cate cholami nes . Intern. Brain Res. Org. Monogr. Ser. 1983; 10: 
147-158
26. Rodríguez de Lores Arnaiz G. In search of synaptosomal Na+, K+-ATPase 
regulators. Molec. Neurobiol. 1992; 6: 359-375.
27. Rodríguez de Lores Arnaiz G. How many endobains are there? Neuro-
chem. Res. 2000; 25; 1421-1430.
28. Kometiani Z, Jariashvili T. The Na/K-ATPase regulation by neu-
rotransmitters in ontogeny. Arch. Physiol. Biochem. 2000; 108: 360-
370.
29. Teixeira VL, Katz AI, Pedemonte CH, Bertorello AM. Isoform-spe-
cific regulation of Na+, K+-ATPase endocytosis and recruitment to the 
plasma membrane. Ann. N. Y. Acad. Sci. 2003; 986: 587-594.
30. Eakle KA, Kabalin MA, Wang SG, Farley RA. The influence of beta 
subunit structure on the stability of Na+/K+-ATPase complexes and 
interaction with K+. J. Biol. Chem. 1994; 269: 6550-6557.
31. Chow DC, Forte JG. Functional significance of the beta-subunit for 
heterodimeric P-type ATPases. J. Exp. Biol. 1995; 198: 1-17.
32. Jaisser F, Horisberger JD, Rossier BC. The beta subunit modulates 
potassium activation of the Na-K pump. Ann. N. Y. Acad. Sci. 1992; 
671: 113-119.
33. Lutsenko S, Kaplan JH. An essential role for the extracellular domain 
of the Na,K-ATPase beta-subunit in cation occlusion. Biochemistry. 
1993; 32: 6737-6743.
34. Beguin P, Wang X, Firsov D, Puoti A, Claeys D, et al. The gamma 
subunit is a specific component of the Na,K-ATPase and modulates its 
transport function. EMBO J. 1997; 16: 4250-4260.
35. Therien AG, Blostein R. Mechanisms of sodium pump regulation. Am. 
J. Physiol. Cell Physiol. 2000; 279: C541-C566.
36. Geering K, Beguin P, Garty H, Karlish S, Fuzesi M, et al. FXYD 
proteins: new tissue- and isoform-specific regulators of Na,K-ATPase. 
Ann. N. Y. Acad. Sci. 2003; 986: 388-394.
37. Sweadner KJ, Rael E. The FXYD gene family of small ion transport 
regulators or channels: cDNA sequence, protein signature sequence, 
and expression. Genomics. 2000; 68: 41-56.
38. Cornelius F, Mahmmoud Y. Functional modulation of the sodium 
pump: the regulatory proteins “Fixit”. News Physiol. Sci. 2003; 18: 
119-124.
39. Morton MJ, Farr GA, Hull M, Capendeguy O, Horisberger JD, et al. 
Association with {beta}-COP regulates the trafficking of the newly 
synthesized Na,K-ATPase. J. Biol. Chem. 2010; 285: 33737-33746.
40. Haas M, Askari A, Xie Z. Involvement of Src and epidermal growth 
factor receptor in the signal-transducing function of Na+/K+-ATPase. J. 
Biol. Chem. 2000; 275: 27832-27837.
41. Xie Z. Molecular mechanisms of Na/K-ATPase-mediated signal trans-
duction. Ann. N. Y. Acad. Sci. 2003; 986: 497-503.
42. Xie Z, Askari A. Na(+)/K(+)-ATPase as a signal transducer. Eur. J. 
Biochem. 2002; 269: 2434-2439.
43. Xie Z, Cai T. Na+-K+-ATPase-mediated signal transduction: from 
protein interaction to cellular function. Mol. Interv. 2003; 3: 157-168.
44. Wang H, Haas M, Liang M, Cai T, Tian J, et al. Ouabain assembles sig-
naling cascades through the caveolar Na+/K+-ATPase. J. Biol. Chem. 
2004; 279:17250-17259.
45. Hansen, O. 2003. No evidence for a role in signal-transduction of Na+/
K+-ATPase interaction with putative endogenous ouabain. Eur. J. Bio-
chem. 270:1916-1919.
46. Liu J, Kesiry R, Periyasamy SM, Malhotra D, Xie Z, et al. Ouabain 
induces endocytosis of plasmalemmal Na/K-ATPase in LLC-PK 1 
cells by a clathrin-dependent mechanism. Kidney Int. 2004; 66: 227-
241.
47. Lai F, Madan N, Ye Q, Duan Q, Li Z, et al. Identification of a mutant 
α1 Na/K-ATPase that pumps but is defective in signal transduction. J. 
Biol. Chem. 2013; 288: 13295-13304.
48. Li Z, Xie Z. The Na/K-ATPase/Src complex and cardiotonic steroid-
activated protein kinase cascades. Pflugers Arch. 2009; 457: 635-644.
49. Kraemer DM, Strizek B, Meyer HE, Marcus K, Drenckhahn D. Kid-
ney Na+, K+-ATPase is associated with moesin. Eur. J. Cell. Biol. 2003; 
82: 87-92.
50. Kim M, Jung J, Park CS, Lee K. Identification of the cofilin-binding 
sites in the large cytoplasmic domain of Na,K-ATPase. Biochimie. 
2002; 84: 1021-1029.
51. Kimura T, Allen PB, Nairn AC, Caplan MJ. Arrestins and spinophilin 
competitively regulate Na+, K+-ATPase trafficking through association 
with a large cytoplasmic loop of the Na+, K+-ATPase. Mol. Biol. Cell. 
Na+, K+-aTPase iN agiNg aNd disease
www.ijbs.org    Int  J  Biomed  Sci    vol. 10  no. 2    June  2014 99
2007; 18: 4508-4518.
52. Yudowski GA, Efendiev R, Pedemonte CH, Katz AI, Berggren PO, 
et al. Phosphoinositide-3 kinase binds to a proline-rich motif in the 
Na+, K+-ATPase alpha subunit and regulates its trafficking. Proc. Natl. 
Acad. Sci. USA. 2000; 97: 6556-6561.
53. Cai T, Wang H, Chen Y, Liu L, Gunning WT, et al. Regulation of 
caveolin-1 membrane trafficking by the Na/K-ATPase. J. Cell. Biol. 
2008; 182: 1153-1169.
54. Rose EM, Koo JC, Antflick JE, Ahmed SM, Angers S, et al. Gluta-
mate transporter coupling to Na,K-ATPase. J. Neurosci. 2009; 29: 
8143–8155.
55. Illarionova NB, Gunnarson E, Li Y, Brismar H, Bondar A, et al. 
Functional and molecular interactions between aquaporins and Na,K-
ATPase. Neuroscience. 2010; 168: 915–925.
56. Barwe SP, Anilkumar G, Moon SY, Zheng Y, Whitelegge JP, et al. 
Novel role for Na,K-ATPase in phosphatidylinositol 3-kinase signaling 
and suppression of cell motility. Mol. Biol. Cell. 2005; 16: 1082-1094.
57. Rajasekaran SA, Rajasekaran AK. Na,KATPase and epithelial tight 
junctions. Front. Biosci. (Landmark Ed.) 2009; 14: 2130-2148.
58. Cai H, Wu L, Qu W, Malhotra D, Xie Z. et al. Regulation of apical 
NHE3 trafficking by ouabain-induced activation of the basolateral 
Na+-K+-ATPase receptor comple. Am. J. Physiol. Cell. Physiol. 2008; 
294: C555-563.
59. a. Desfrere L, Karlsson M, Hiyoshi H, Malmerjö S; Nanou E, et al. 
Na,K-ATPase signal transduction triggers CREB activation and den-
dritic growth. Proc. Natl. Acad. Sci. USA. 2009; 106: 2212-2217. b. 
Johar K, Priya A, Dhar S, Liu Q, Wong-Riley MT. Neuron-specific 
specificity protein 4 bigenomically regulates the transcription of all 
mitochondria- and nucleus-encoded cytochrome c oxidase subunit 
genes in neurons. J. Neurochem. 2013; 127:496-508. c. Johar K, Priya 
A, Wong-Riley MT. Regulation of Na(+)/K(+)-ATPase by neuron-
specific transcription factor Sp4: implication in the tight coupling of 
energy production, neuronal activity and energy consumption in neu-
rons. Eur. J. Neurosci. 2014; 39: 566-578. 
60. Bertoni JM, Siegel GJ. Development of (Na+-K+)-ATPase in rat 
cerebrum: correlation with Na+-dependent phosphorylation and 
K+-paranitrophenylphosphatase. J. Neurochem. 1978; 31: 1501-1511.
61. Schmitt CA, MacDonough AA. Developmental and thyroid hormone 
regulation of two molecular forms of Na+, K+-ATPase in brain. J. Biol. 
Chem. 1986; 261: 10439-10444. 
62. Valcana T, Timiras PS. Effect of hypothyroidism on ionic metabolism 
and Na-K activated ATP phosphohydrolase activity in the developing 
rat brain. J. Neurochem. 1969; 16: 935-943.
63. Schmitt CA, MacDonough AA. Thyroid hormone regulates and iso-
forms of Na+, K+-ATPase during development in neonatal rat brain J. 
Biol. Chem. 1988; 263: 17643-17649. 
64. Benzi G, Gorini A, Arnaboldi R, Ghigini B, Villa RF. Age-related 
alterations by chronic intermittent hypoxia on cerebral synaptosomal 
ATPase activities. J. Neural Transm Suppl. 1994; 44: 159-171.
65. Chauhan NB, Siegel GJ. In situ analysis of Na, K-ATPase alpha1- and 
alpha3-isoform mRNAs in aging rat hippocampus. J. Neurochem. 
1996; 66: 1742-1751.
66. Chauhan N, Siegel G. Differential expression of Na, K-ATPase alpha-
isoform mRNAs in aging rat cerebellum. J. Neurosci. Res. 1997a; 47: 
287-299. 
67. Chauhan NB, Siegel GJ. Na, K-ATPase: increases in alpha1-messenger 
RNA and decreases in alpha3-messenger RNA levels in aging rat cere-
bral cortex. Neuroscience. 1997b; 78: 7-11. 
68. Biser PS, Thayne KA, Kong JQ, Fleming WW, Taylor DA. Quantifica-
tion of the alpha(3) subunit of the Na(+)/K(+)-ATPase in developing rat 
cerebellum. Brain Res. Dev. Brain Res. 2000; 123: 165-172.
69. Kocak H, Oner P, Oztaş B. Comparison of the activities of the Na(+), 
K(+)-ATPase in brains of rats at different ages. Gerontology. 2002; 
48: 279-281.
70. Cohadon F, Desbordes P. Brain water and aging. Gerontology. 1986; 
32 Suppl. 1: 46-49. 
71. Tanaka Y, Ando S. Synaptic aging as revealed by changes in mem-
brane potential and decreased activity of Na(+), K(+)-ATPase. Brain 
Res. 1990; 506: 46-52.
72. Ando S, Tanaka Y. Synaptic membrane aging in the central nervous 
system. Gerontology. 1990; 36 Suppl 1: 10-14.
73. Tanaka Y, Ando S. Age-related changes in [3H] ouabain binding to 
synaptic plasma membranes isolated from mouse brains. J. Biochem. 
1992; 112: 117-121.
74. Meier-Ruge W, Iwangoff P, Reichlmeier K, Sadoz P. Neurochemical 
findings in the aging brain. Adv. Biochem. Psychopharmacol. 1980; 
23: 323-338. 
75. Harik SI, Mitchell MJ, Kalaria RN. Ouabain Binding in the Human 
Brain. Arch. Neurol. 1989; 46: 951-954.
76. Kennedy RH, Akera T, Katano Y. Aging: effects on sodium- and 
potassium-activated adenosine triphosphatase activity and ouabain 
binding sites in rat brain. J. Gerontol. 1985; 40: 401-408.
77. Fraser CL, Arieff AI. Na-K-ATPase activity decreases with aging in 
female rat brain synaptosomes Am. J. Physiol. Renal Physiol. 2001; 
281: F674-F678.
78. Chakraborty H, Sen P, Sur A, Chatterjee U, Chakrabarti S. Age-
related oxidative inactivation of Na+, K+-ATPase in rat brain crude 
synaptosomes. Exp. Gerontol. 2003; 38: 705-710. 
79. Chauhan NB, Lee JM, Siegel GJ. Na,K-ATPase mRNA levels and 
plaque load in Alzheimer s´ disease. J. Mol. Neurosci. 1997; 9: 151-166. 
80. Gorini A, Canosi U, Devecchi E, Geroldi D, Villa RF. ATPases 
enzyme activities during ageing in different types of somatic and syn-
aptic plasma membranes from rat frontal cerebral cortex. Prog. Neuro-
psychopharmacol. Biol. Psychiatry. 2002; 26: 81-90.
81. Reime Kinjo E, Arida RM, Mara de Oliveira D, da Silva Fernandes 
MJ. The Na+, K+-ATPase activity is increased in the hippocampus after 
multiple status epilepticus induced by pilocarpine in developing rats. 
Brain Res. 2007; 1138: 203-207.
82. Grady CL. Cognitive neuroscience of aging. Ann. N. Y. Acad. Sci. 
2008; 1124: 127-144.
83. Singh R, Mishra M, Singh S, Sharma D. Effect of L-deprenyl treatment 
on electrical activity, Na+, K+-ATPase, and protein kinase C activities 
in hippocampal subfields (CA1 and CA3) of aged rat brain. Indian J. 
Exp. Biol. 2012; 50: 101-109.
84. Villa RF, Gorini A, Hoyer S. ATPases of Synaptic Plasma Membranes 
from Hippocampus after Ischemia and Recovery during Ageing. Neu-
rochem. Res. 2002; 27: 861-870.
85. Leenen FH, Harmsen E, Yu H. Dietary sodium and central vs. periph-
eral ouabain-like activity in Dahl salt-sensitive vs. salt-resistant rats. 
Am. J. Physiol. 1994; 267: H1916-H1920.
86. Chow MK, Shao Q, Ren B, Leenen FH, Van Huysse JW. Changes in 
brain Na, K-ATPase isoform expression and enzymatic activity after 
aortic constriction. Brain Res. 2002; 944: 124-134. 
87. Anner BM, Imesch E, Moosmayer M. Normal sensitivity of Na+, K+-
ATPase isolated from brain and kidney of spontaneouly hypertensive 
rats to sodium, ouabain or mercury. Biochim. Biophys. Acta. 1995; 
1270: 95-99.
88. Lees GJ. Inhibition of sodium-potassium-ATPase: a potentially ubiq-
uitous mechanism contributing to central nervous system neuropathol-
ogy. Brain Res. Brain Res. Rev. 1991; 16: 283-300. 
89. Kempski O. Cerebral edema. Semin. Nephrol. 2001; 21: 303-307.
90. Masocha W, Horvath C, Agil A, Ocana M, Del Pozo E, et al. Role of 
Na+, K+-ATPase in morphine-induced antinociception. J. Pharmacol. 
Exp. Ther. 2003; 306: 1122-1128. 
Na+, K+-aTPase iN agiNg aNd disease
June  2014    Vol. 10  No. 2    Int  J  Biomed  Sci    www.ijbs.org 100
91. Mintorovitch J, Yang GY, Shimizu H, Kucharczyk J, Chan PH, et al. 
Diffusion-weighted magnetic resonance imaging of acute focal cere-
bral ischemia: comparison of signal intensity with changes in brain 
water and Na(+), K(+)-ATPase activity. J. Cerebr. Blood Flow Metab. 
1994; 14: 332-336.
92. Jamme I, Petit E, Gerbi A., Maixent JM, MacKenzie ET, et al. Changes 
in ouabain affinity of Na+,K+-ATPase during focal cerebral ischaemia 
in the mouse. Brain Res. 1997; 774: 123-130.
93. Jamme I, Barbey O, Trouve P, Charlemagne D, Maixent JM, et al. 
Focal cerebral ischaemia induces a decrease in activity and a shift in 
ouabain affinity of Na+, K+-ATPase isoforms without modifications in 
mRNA and protein expression. Brain Res. 1999; 819: 132-142.
94. de Souza Wyse AT, Streck EL, Worm P, Wajner A, Ritter F, et al. Pre-
conditioning prevents the inhibition of Na+, K+-ATPase activity after 
brain ischemia. Neurochem. Res. 2000; 25: 971-975.
95. Tian D, Dmitrieva RI, Doris PA, Crary JF, Sondhi R, et al. Protein 
kinase M zeta regulation of Na/K-ATPase: a persistent neuroprotective 
mechanism of ischemic preconditioning in hippocampal slice cultures. 
Brain Res. 2008; 1213: 127-139. 
96. Lichtstein D, Samuelov S, Bourrit A. Characterization of the stimula-
tion of neuronal Na(+), K(+)-ATPase activty by low concentrations of 
ouabain. Neurochem. Int. 1985; 7: 709-715.
97. Oselkin M, Tian D, Bergold PJ. Low-dose cardiotonic steroids increase 
sodium-potassium ATPase activity that protects hippocampal slice 
cultures from experimental ischemia. Neurosci. Lett. 2010; 473: 67-71. 
98. Zhan L, Peng W, Sun W, Xu E. Hypoxic preconditioning induces neu-
roprotection against transient global ischemia in adult rats via preser-
vation the activity of Na+, K+-ATPase. Neurochem. Int. 2011; 59: 65-72. 
99. Silva LF, Hoffmann MS, Rambo LM, Ribeiro LR, Lima FD, et al. The 
involvement of Na+, K+-ATPase activity and free radical generation in 
the susceptibility to pentylenetetrazol-induced seizures after experi-
mental traumatic brain injury. J. Neurol. Sci. 2011; 308: 35-40.
100. Mota BC, Pereira L, Souza MA, Silva LF, Magni DV, et al. Exercise 
pre-conditioning reduces brain inflammation and protects against tox-
icity induced by traumatic brain injury: behavioral and neurochemical 
approach. Neurotox. Res. 2012; 21: 175-184.
101. Bagrov AY, Bagrov YY, Fedorova OV, Kashkin VA, Patkina NA, et 
al. Endogenous digitalis-like ligands of the sodium pump: possible 
involvement in mood control and ethanol addiction. Eur. Neuropsy-
chopharmacol. 2002; 12: 1-12. 
102. Traub N, Lichtstein D. The mood cycle hypothesis: possible involve-
ment of steroid hormones in mood regulation by means of Na+, K+-
ATPase inhibition. J. Basic Clin. Physiol. Pharmacol. 2000; 11: 375-
394.
103. Kendler KS, Thornton LM, Gardner CO. Genetic risk, number of pre-
vious depressive episodes, and stressful life events in predicting onset 
of major depression. Am. J. Psychiatry. 2001; 158: 582-586.
104. Naylor GJ, Smith AH, Dick EG, Dick DA, McHarg AM, et al. Erythro-
cyte membrane cation carrier in manic-depressive psychosis. Psycol. 
Med. 1980; 10: 521-525. 
105. Hokin-Neaverson M, Jefferson JW. Deficient erythrocyte NaK-
ATPase activity in different affective states in bipolar affective disor-
der and normalization by lithium therapy. Neuropsychobiology. 1989; 
22: 18-25. 
106. Wood AJ, Smith CE, Clarke EE, Cowen PJ, et al. Altered in vitro adap-
tive responses of lymphocyte Na(+), K(+)-ATPase in patients with 
manic depressive psychosis. J. Affect. Disord. 1991; 21: 199-206. 
107. Tochigi M, Iwamoto K, Bundo M, Sasaki T, Kato N, et al. Gene expres-
sion profiling of major depression and suicide in the prefrontal cortex 
of postmortem brains. Neurosci. Res. 2008; 60: 184-191.
108. Gamaro GD, Streck EL, Matte C, Prediger ME, Wyse AT. Reduction 
of hippocampal Na+, K+-ATPase activity in rats subjected to an experi-
mental model of depression. Neurochem. Res. 2003; 28: 1339-1344.
109. a. de Vasconcellos AP, Zugno AI, Dos Santos AH, Nietto FB, Crema 
LM, et al. Na+, K+-ATPase activity is reduced in hippocampus of rats 
submitted to an experimental model of depression: effect of chronic 
lithium treatment and possible involvement in learning deficits. Neu-
robiol. Learn. Mem. 2005; 84: 102-110. b. Pinacho R, Villalmanzo N, 
Lalonde J, Haro JM, Meana JJ, et al. The transcription factor SP4 is 
reduced in postmortem cerebellum of bipolar disorder subjects: con-
trol by depolarization and lithium. Bipolar Disord. 2011; 13: 474-485.
110. Kirshenbaum GS, Saltzman K, Rose B, Petersen J, Vilsen B, et al. 
Decreased neuronal Na+,K+-ATPase activity in Atp1a3 heterozygous 
mice increases susceptibility to depression-like endophenotypes by 
chronic variable stress. Genes Brain Behav. 2011; 10: 542-550. 
111. Yu JJ, Zhang Y, Wang Y, Wen ZY, Liu XH, et al. Inhibition of calcineu-
rin in the prefrontal cortex induced depressive-like behavior through 
mTOR signaling pathway. Psychopharmacology (Berl). 2013; 225: 
361-372.
112. El-Mallakh RS, El-Masri MA, Huff MO, Li XP, Decker S, et al. Intra-
cerebroventricular administration of ouabain as a model of mania in 
rats. Bipolar Disord. 2003; 5: 362-365.
113. Kim SH, Yu HS, Park HG, Jeon WJ, Song JY, et al. Dose-dependent 
effect of intracerebroventricular injection of ouabain on the phos-
phorylation of the MEK1/2-ERK1/2-p90RSK pathway in the rat brain 
related to locomotor activity. Prog. Neuropsychopharmacol. Biol. 
Psychiatry. 2008; 32: 1637-1642.
114. Yu HS, Kim SH, Park HG, Kim YS, Ahn YM. Activation of Akt sig-
naling in rat brain by intracerebroventricular injection of ouabain: a 
rat model for mania. Prog. Neuropsychopharmacol. Biol. Psychiatry. 
2010; 34: 888-894.
115. Yu HS, Kim SH, Park HG, Kim YS, Ahn YM. Intracerebroventricular 
administration of ouabain, a Na/K-ATPase inhibitor, activates tyro-
sine hydroxylase through extracellular signal-regulated kinase in rat 
striatum. Neurochem. Int. 2011; 59: 779-786.
116. Hilgenberg LG, Su H, Gu H, O´Dowd DK, Smith MA. Alpha3 Na+/
K+-ATPase is a neuronal receptor for agrin. Cell. 2006; 125: 359-369.
117. Kirshenbaum GS, Clapcote SJ, Duffy S, Burgess CR, Petersen J, et 
al. Mania-like behavior induced by genetic dysfunction of the neuron-
specific Na+,K+-ATPase α3 sodium pump. Proc. Natl. Acad. Sci. USA. 
2011b; 108: 18144-18149.
118. Kirshenbaum GS, Clapcote SJ, Petersen J, Vilsen B, Ralph MR, et al. 
Genetic suppression of agrin reduces mania-like behavior in Na+, K+-
ATPase alpha3 mutant mice. Genes Brain Behav. 2012; 11: 436-443.
119. Silveira PP, Portella AK, Benetti Cda S, Zugno AI, Scherer EB, et al. 
Association between Na+, K+-ATPase activity and the vulnerability/
resilience to mood disorders induced by early life experience. Neuro-
chem. Res. 2011; 36: 2075-2082.
120. Balk RdeS, Silva MH, Bridi JC, Carvalho NR, Portella RdeL, et al. 
Effect of repeated restraint stress and clomipramine on Na+/ K+-
ATPase activity and behavior in rats. Int. J. Dev. Neurosci. 2011; 29: 
909-916.
121. Renkawek K, Renier WO, de Pont JJ, Vogels OJ, Gabreels FJ. Neonatal 
status convulsivus, spongiform encephalopathy, and low activity of 
Na+, K+-ATPase in the brain. Epilepsia. 1992; 33: 58-64. 
122. De Robertis E, Alberici M, Rodríguez de Lores Ar naiz G. Astro glial 
swelling and phosphohydrolases in cerebral cortex of metrazol convul-
sant rats. Brain Res. 1969; 12: 461-466 .
123. Guillaume D, Grisar T, Delgado-Escueta AV, Bureau-Heeren M, Las-
chet J. Phosphorylation of brain (Na+, K+)-ATPase alpha catalytic sub-
units in normal and epileptic cerebral cortex: I. The audiogenic mice 
and the cat with a freeze lesion. J. Neurosci. Res. 1991; 29: 207-217. 
124. Xiong ZQ, Stringer JL. Sodium pump activity, not glial spatial buffer-
ing, clears potassium after epileptiform activity induced in the dentate 
Na+, K+-aTPase iN agiNg aNd disease
www.ijbs.org    Int  J  Biomed  Sci    vol. 10  no. 2    June  2014 101
gyrus. J. Neurophysiol. 2000; 83: 1443-1451.
125. Vaillend C, Mason SE, Cuttle MF, Alger BE. Mechanisms of Neuronal 
Hyperexcitability Caused by Partial Inhibition of Na+-K+-ATPases in 
the Rat CA1 Hippocampal Region. J. Neurophysiol. 2002; 88: 2963-
2978.
126. Tavraz NN, Friedrich T, Dürr KL, Koenderink JB, Bamberg E, et al. 
Diverse functional consequences of mutations in the Na+/K+-ATPase 
alpha2-subunit causing familial hemiplegic migraine type 2. J. Biol. 
Chem. 2008; 283: 31097-31106.
127. Jurkat-Rott K, Freilinger T, Dreier JP, Herzog J, Göbel H, et al. Vari-
ability of familial hemiplegic migraine with novel A1A2 Na+, K+-
ATPase variants. Neurology. 2004; 62: 1857-1861.
128. Clapcote SJ, Duffy S, Xie G, Kirshenbaum G, Bechard AR, et al. 
Mutation I810N in the alpha3 isoform of Na+,K+-ATPase causes 
impairements in the sodium pump and hyperexcitability in the CNS. 
Proc. Natl. Acad. Sci. USA. 2009; 106: 14085-14090.
129. Thomsen LL, Ostergaard E, Olesen J, Russell MB. Evidence for a 
separate type of migraine with aura: sporadic hemiplegic migraine. 
Neurology. 2003; 60: 595-601.
130. Gallanti A, Tonelli A, Cardin V, Bussone G, Bresolin N, et al. A 
novel de novo nonsense mutation in ATP1A2 associated with sporadic 
hemiplegic migraine and epileptic seizures. J. Neurol. Sci. 2008; 273: 
123-126.
131. Bøttger P, Doğanli C, Lykke-Hartmann K. Migraine- and dystonia-
related disease-mutations of Na+/K+-ATPases: relevance of behavioral 
studies in mice to disease symptoms and neurological manifestations 
in humans. Neurosci. Biobehav. Rev. 2012; 36: 855-871.
132. Khan FH, Sen T, Chakrabarti S. Dopamine oxidation products inhibit 
Na+, K+-ATPase activity in crude synaptosomal-mitochondrial frac-
tion from rat brain. Free Radic. Res. 2003; 37: 597-601.
133. Aperia A. new roles for an old enzyme: Na, K-ATPase emerges as an 
interesting drug target. J. Intern. Med. 2007; 261: 44-52.
134. Kim SH, Yu HS, Park HG, Ha K, Kim YS, et al. Intracerebroven-
tricular administration of ouabain, a Na/K-ATPase inhibitor, activates 
mTOR signal pathways and protein translation in the rat frontal cortex. 
Prog. Neuropsychopharmacol. Biol. Psychiatry. 2013; 45C:73-82.
135. Silva LF, Hoffmann MS, Gerbatin Rda R, Fiorin Fda S, Dobrachinski 
F, et al. Treadmill exercise protects against pentylenetetrazol-induced 
seizures and oxidative stress after traumatic brain injury. J. Neuro-
trauma. 2013; 30: 1278-1287. 
136. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathol-
ogy of Alzheimer disease. Acta Neuropathol. 2009; 118: 5-36.
137. Wong PC, Savonenko A, Li T, Price DL. Neurobiology of Alzheimer s´ 
Disease. In: Brady ST, Siegel GJ, Albers RW, Price D (Eds.), Basic 
Neurochemistry: Principles of Molecular, Cellular and Medical Neu-
robiology, 8th edn. Massachusetts, USA: Elsevier Academic Press. 
2012; 815-828. 
138. Liguri G, Taddei N, Nassi P, Latorraca S, Neidiani C, et al. Changes 
in Na+, K+-ATPase, Ca2+-ATPase and some soluble enzymes related 
to energy metabolism in brains of patients with Alzheimer s´ disease. 
Neurosci. Lett. 1990; 112: 338-342.
139. Marck RJ, Hensley K, Butterfield DA, Mattson MP. Amyloid beta-
peptide impairs ion-motive ATPase activities: evidence for a role in 
loss of neuronal Ca2+ homeostasis and cell death. J. Neurosci. 1995; 
15: 6239-6249.
140. Marck RJ, Pang Z, Geddes JW, Uchida K, Mattson MP. Amyloid 
beta-peptide impairs glucose transport in hippocampaland cortical 
neurons: Involvement of membrane lipid peroxidation. J. Neurosci. 
1997b; 17: 1046-1054.
141. Marck RJ, Keller JN, Kruman I, Mattson MP. Basic FGF attenuates 
beta-peptide-induced oxidative stress, mitochondrial dysfunction, and 
impairment of Na+/K+-ATPase activity hippocampal neurons. Brain 
Res. 1997; 756: 205-214.
142. Bores GM, Smith CP, Wirtz-Brugger F, Giovanni A. Amyloid beta-
peptides inhibit Na+, K+-ATPase: tissue slices versus primary cultures. 
Brain Res. Bull. 1998; 46: 423-427.
143. Hattori N, Kitagawa K, Higashida T, Yagyu K, Shimohama S, et al. Cl-
-ATPase and Na+, K+-ATPase activities in Alzheimer s´ disease brains. 
Neurosci. Letters. 1998; 254: 141-144. 
144. Braithwaite SP, Stock JB, Lombroso PJ, Nairn AC. Protein phospha-
tases and Alzheimer s´ disease. Prog. Mol. Biol. Transl. Sci. 2012; 106: 
343-379.
145. Karch CM, Jeng AT, Goate AM. Calcium phosphatase calcineurin 
influences tau metabolism. Neurobiol. Aging. 2013; 34: 374-386.
146. Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkaine A, et al. 
Amyloid beta induces the morphological neurodegenerative triad of 
spine loss, dendritic simplification, and neuritic dystrophies through 
calcineurin activation. J. Neurosci. 2010; 30: 2636-2649.
147. Benilova I, Karran E, De Strooper B. The toxic A β oligomer and 
Alzheimer s´ disease: an emperor in need of clothes. Nat. Neurosci. 
2012; 15: 349-357.
148. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, et al. Metabo-
tropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer 
bound to cellular prion protein. Neuron. 2013; 79: 887-902.
149. Jo J, Whicomb DJ, Olsen KM, Kerrigan TL, Lo SC, et al. Abeta(1-42) 
inhibition of LTP is mediated by a signaling pathway involving cas-
pase-3, Akt1 and GSK-3beta. Nat. Neurosci. 2011; 14: 545-547.
150. Deng Y, Xiong Z, Chen P, Wei J, Chen S, et al. β-Amyloid impairs the 
regulation of N-methyl-D-aspartate receptors by glycogen synthase 
kinase 3. Neurobiol. Aging. 2013 [Epub ahead].
151. Wang ZC, Zhao J, Li S. Dysregulation of synaptic and extrasynaptic 
N-methyl-D-aspartate receptors induced by amyloid-β. Neurosci. Bull. 
2013; oct 17 [Epub ahead of print]
152. Rodríguez de Lores Arnaiz G. Interplay between Na+, K+-ATPase and 
neurotransmitter receptors. In: Richard R. (Ed.). Current Topics in 
Neurochemistry, Vol. 3, Trivandrum, India: Research Trends. 2002; 
p189-198.
153. Bersier MG, Peña C, Rodríguez de Lores Arnaiz G. The expression 
of NMDA receptor subunits in cerebral cortex and hippocampus is 
differentially increased by administration of endobain E, a Na+, K+-
ATPase inhibitor. Neurochem. Res. 2008; 33: 66-72. 
154. Bersier MG, Rodríguez de Lores Arnaiz G. Intracerebroventricular 
administration of ouabain to rats changes the expression of NMDA 
receptor subunits in cerebral cortex and hippocampus. Neurochem. 
Res. 2009; 34: 1650-1657.
155. Unoki T, Matsuda S, Kakegawa W, Van NT, Kohda K, et al. NMDA 
receptor-mediated PIP5K activation to produce PI(4,5)P2 is essential 
for AMPA receptor endocytosis during LTD. Neuron. 2012; 73: 135-
148.
156. Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, et al. Effects 
of steroid hormones on (Na+, K+)-ATPase activity inhibition-induced 
amnesia on the step-through passive avoidance task in gonadecto-
mized mice. Pharmacol. Res. 2004; 49: 151-159.
157. Stevens MJ, Dananberg J, Feldman EL, Lattimer SA, Kamijo M, et 
al. The linked roles of nitric oxide, aldose reductase and (Na+- K+)-
ATPase in the slowing of nerve conduction in the streptozotocin dia-
betic rat. J. Clin. Invest. 1994; 94: 853-859.
158. Garvryck WA, Moore RD, Thompson RC. Effect of insulin upon 
membrane-bound (Na+/ K+-ATPase)-ATPase extracted from skeletal 
muscle. J. Physiol. 1975; 252: 43-58.
159. Bojorge G, Rodríguez de Lores Arnaiz G. Insulin modi fies Na+, 
K+-ATPase activity of synaptosomal membranes and whole homog ena-
tes prepa red from rat cerebral cortex. Neurochem. Int. 1987; 11: 11-16.
160. Brodsky JL. Insulin activation of brain Na(+) + K(+) ATPase is medi-
Na+, K+-aTPase iN agiNg aNd disease
June  2014    Vol. 10  No. 2    Int  J  Biomed  Sci    www.ijbs.org 102
ated by alpha 2-isoform of enzyme. American J. Physiol. 1990; 258 
Issue 5 Pt. 1, C812-C817.
161. Szkudelski T. The mechanism of alloxan and streptozotocin action in B 
cells of the rat pancreas. Physiol. Res. 2001; 50: 537-546.
162. Vér A, Csermely P, Bányász T, Kovács T, Somogyi J. Alterations in the 
properties and isoform ratios of brain Na+/ K+-ATPase in streptozoto-
cin diabetic rats. Biochim. Biophys. Acta. 1995; 1237: 143-150.
163. Michea L, Irribarra V, Goecke IA, Marusic ET. Reduced Na-K pump 
but increased Na-K-2Cl cotransporter in aorta of streptozotocin-in-
duced diabetic rat. Am. J. Physiol. Heart Circ. Physiol. 2001; 280: 
H851-H858.
164. Zarros A, Liapi C, Galanopoulou P, Marinou K, Mellios Z, et al. Effects 
of adult-onset streptpzotocin-induced diabetes on the rat brain antioxi-
dant status and the activities of acetylcholinesterase, Na(+),K(+))- and 
Mg(2+)-ATPase: modulation by cysteine. Metab. Brain Dis. 2009; 24: 
337-348.
165. López Ordieres MG, Rosin C, Miño J, Rodríguez de Lores Arnaiz G. 
Na+, K+-ATPase response to neurotensin is altered by streptozotocin 
administration. Current Topics in Peptide & Protein Research. 2013 
(in press).
166. Lefranc F, Mijatovic T, Kiss R. The sodium pump could constitute a 
new target to combat gliobastomas. Bull. Cancer. 2008; 95: 271-281.
167. Lefranc F, Kiss R. The sodium pump alpha1 subunit as a potential 
target to combat apoptosis-resistant gliobastomas. Neoplasia. 2008; 
10: 198-206.
168. Wang MW, Gu P, Zhang ZL, Zhu ZL, Geng Y, et al. FXYD3 expres-
sion in gliomas and its clinicopathological significance. Oncol. Res. 
2009; 18: 133-139. 
169. Rodríguez de Lores Arnaiz G, De Robertis E. Properties of the iso-
lated nerve endings. In: Bronner F, Kleinzeller A (Eds.) Current Topics 
in Membranes and Tr ansport, Vol. III. Nueva York, USA: Ac ade mic 
Press. 1972; p237-272.
170. Zhang NY, Sillar KT. Short-term memory of network performance via 
activity-dependent potentiation of Na+/K+ pump function. Curr. Biol. 
2013; 22: 526-531. 
171. a. Lundborg C, Westerlund A, Björklund U, Biber B, Hansson E. 
Ifenprodil restores GDNF-evoked Ca(2+) signaling and Na(+)/K(+)-
ATPase expression in inflammation-pretreated astrocytes. J. Neuro-
chem. 2011; 119: 686-696. b. Boutillier S, Lannes B, Buée L, Dela-
courte A, Rouaux C, et al. Sp3 and Sp4 transcription factor levels are 
increased in brains of patients with Alzheimer disease. Neurodegener. 
Dis. 2007; 4: 413-423. 
